doi: 10.3389/fphar.2025.1632588 Received 21 May 2025 Accepted 28 July 2025 Published 29 August 2025 Volume 16 - 2025 Edited by Yurong Lai, Gilead, United States Reviewed by Daniel Crona, University of North Carolina at Chapel Hill, United States John Prybylski, Pfizer, United States Updates Copyright 2025 Cao, Qian, Wang, Zheng, Huang, Wei, Jiang, Yu, Jiang, Yu, Mao and Zhai
This CDPFPCTS/EDTA NS exploits the simultaneous chelating ability of CTS and EDTA
IV therapy frequency is the schedule of intravenous infusion sessions that best supports your specific health goals, ranging from multiple times per week during acute needs to once monthly for general maintenance
Briefly, one article reported in vitro and in vivo effects of curcumin